Gene Therapy for Gaucher Disease Enzyme Deficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Gaucher disease primarily focus on symptom relief rather than addressing the underlying cause, with enzyme replacement therapy providing short-lived benefits and requiring frequent administration, which is costly and affects patient compliance.
Innovation Solution
The use of agents that increase the expression and activity of β-glucocerebrosidase (GBA) and scavenger receptor class B member 2 (SCARB2) through polynucleotides, interfering RNA molecules, and small molecules, administered via various routes including intracerebroventricular and intravenous, to treat Gaucher disease by targeting the underlying physiological cause.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy (ERT) is administered frequently to maintain therapeutic benefit, then the disease symptoms are controlled, but treatment cost increases and patient compliance deteriorates
Solution Approach 1:
The patent uses gene therapy to preliminarily introduce functional GBA genes into patient cells, establishing long-term endogenous enzyme production capacity before clinical need arises. This preliminary genetic modification eliminates the need for repeated ERT administrations, resolving the compliance issue while maintaining reliable disease control through sustained enzyme production from modified cells
Solution Approach 2:
The patent enables patient cells to serve themselves by endogenously producing functional GBA enzyme through introduced genes. The modified cells continuously produce and secrete the enzyme they need, eliminating dependence on external ERT administrations. This self-service mechanism maintains reliable symptom control without requiring frequent medical interventions, thereby improving patient compliance
2Reliability
If enzyme replacement therapy (ERT) is administered frequently to maintain therapeutic benefit, then the disease symptoms are controlled, but treatment cost increases
Solution Approach 1:
The patent performs preliminary gene introduction to establish long-term enzyme production capability, avoiding the need for continuous expensive ERT purchases. This one-time or limited gene therapy intervention replaces ongoing costly enzyme replacements, maintaining reliable symptom control while dramatically reducing treatment costs
Solution Approach 2:
By enabling cells to self-produce functional GBA enzyme, the patent eliminates the need for continuous external enzyme supply. This self-sufficiency mechanism maintains reliable disease control without the recurring cost of ERT, effectively resolving the cost burden while preserving therapeutic reliability
3Loss of time
If current treatments focus on symptom relief rather than underlying cause, then short-term symptom management is achieved, but long-term disease resolution is not attained
Solution Approach 1:
The patent extracts and addresses the root cause of Gaucher disease by introducing functional GBA genes to correct the underlying enzymatic deficiency. Rather than merely managing symptoms, this approach tackles the fundamental genetic defect, enabling long-term disease resolution while reducing the time spent on repetitive symptom management
Solution Approach 2:
The patent takes preliminary action to correct the underlying genetic cause through gene introduction, preventing future symptom recurrence rather than merely responding to symptoms as they occur. This proactive approach to root cause correction achieves both reduced time loss from symptom management and reliable long-term disease resolution
Data Source
AI summary
Described herein are methods for treating a subject having or at risk of developing Gaucher disease, by administering one or more agents that increase expression and/or activity of glucocerebrosidase (GBA) and/or scavenger receptor class B member 2 (SCARB2), such as pluripotent cells that express GBA and/or SCARB2, and to the subject. Also disclosed are compositions comprising one or more agents that increase the expression and/or activity of GBA and/or SCARB2.